Progyny (PGNY) Tops Q3 Earnings Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2024
0mins
Should l Buy PGNY?
Source: NASDAQ.COM
Earnings Performance: Progyny (PGNY) reported quarterly earnings of $0.40 per share, exceeding estimates and showing significant growth from $0.16 a year ago, but its revenues of $286.63 million fell short of expectations.
Stock Outlook: Despite the positive earnings surprise, Progyny's stock has underperformed this year, with a Zacks Rank #4 (Sell) indicating expected further underperformance, influenced by unfavorable estimate revisions and the overall industry ranking.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 18.180
Low
26.00
Averages
29.75
High
34.00
Current: 18.180
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Small Cap Stocks Attractive Amid Stagflation Risks
- Stagflation Risks: The U.S. economy faces stagflation risks, with February's Producer Price Index (PPI) rising 3.4% year-over-year and core PPI at 3.9%, intensifying concerns over low growth and high inflation, which has led to increased market volatility.
- Increased Market Volatility: The CBOE Volatility Index (VIX) recently reached about 23, indicating rising market uncertainty and heightened investor fear, particularly in the small-cap sector where investors are favoring high-quality stocks with cash returns.
- Small Cap Screening: Bank of America identified small-cap stocks in the top quintile for both value and quality, focusing on companies that have paid dividends or reduced share counts over the past 12 months to mitigate potential stagflation risks.
- Stock Performance: Bread Financial is rated a buy, despite being down 12% from its recent high, it has risen 1.5% this month; Progyny is down 37% but up 2% this week, indicating potential opportunities in small-cap stocks amid market uncertainty.
See More
PROGYNY INC - SHAREHOLDER LAWSUIT FILED AGAINST PROGYNY BOARD REGARDING DIRECTOR PAY - SEC FILING
Legal Action Against Progyny: A derivative action has been initiated against the board of directors of Progyny, focusing on issues related to compensation.
Compensation Concerns: The legal filing raises questions about the appropriateness and structure of compensation for Progyny's directors.
See More
Progyny Inc Stock Shows Oversold Signal
- Oversold Indicator: Progyny Inc (Ticker: PGNY) hit an RSI of 29.9 during Monday's trading, indicating an oversold condition as shares dipped to $17.77, suggesting that recent heavy selling may be nearing exhaustion, prompting investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, PGNY's 29.9 RSI reflects relative weakness, potentially attracting investors looking for rebounds and increasing market participation.
- Historical Performance: PGNY's 52-week low stands at $16.755 and the high at $28.75, with the current trading price at $17.75, indicating potential rebound space within its volatility range, which may attract short-term traders.
- Investor Sentiment: As PGNY approaches its 52-week low, investor sentiment may shift to optimism, especially in light of the oversold signal, potentially encouraging more investors to seek entry points to capture potential rebounds.
See More
Progyny Leadership to Participate in Investor Conferences
- Investor Conference Schedule: Progyny's leadership team will participate in several investor conferences in March, including Leerink Partners, Barclays, and KeyBanc, showcasing the company's leadership in women's health and family building solutions.
- Executive Participation: CFO Mark Livingston will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, while CEO Pete Anevski will participate in a fireside chat at the Barclays Global Healthcare Conference on March 11, enhancing the company's visibility.
- Technology Discussion: COO Melissa Cummings will join a panel discussion on fertility technology and women's health at the KeyBanc Capital Markets Healthcare Forum on March 17, highlighting Progyny's expertise and innovation in the field.
- Live Streaming: Live audiocasts and replays of all fireside chats will be available in the Events and Presentations section of Progyny's investor relations website, ensuring investors can stay updated on the company's latest developments.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Progyny Reports Record Revenue and EBITDA for 2025
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
See More
Small Cap Stocks Attractive Amid Stagflation Risks
- Stagflation Risks: The U.S. economy faces stagflation risks, with February's Producer Price Index (PPI) rising 3.4% year-over-year and core PPI at 3.9%, intensifying concerns over low growth and high inflation, which has led to increased market volatility.
- Increased Market Volatility: The CBOE Volatility Index (VIX) recently reached about 23, indicating rising market uncertainty and heightened investor fear, particularly in the small-cap sector where investors are favoring high-quality stocks with cash returns.
- Small Cap Screening: Bank of America identified small-cap stocks in the top quintile for both value and quality, focusing on companies that have paid dividends or reduced share counts over the past 12 months to mitigate potential stagflation risks.
- Stock Performance: Bread Financial is rated a buy, despite being down 12% from its recent high, it has risen 1.5% this month; Progyny is down 37% but up 2% this week, indicating potential opportunities in small-cap stocks amid market uncertainty.
See More
PROGYNY INC - SHAREHOLDER LAWSUIT FILED AGAINST PROGYNY BOARD REGARDING DIRECTOR PAY - SEC FILING
Legal Action Against Progyny: A derivative action has been initiated against the board of directors of Progyny, focusing on issues related to compensation.
Compensation Concerns: The legal filing raises questions about the appropriateness and structure of compensation for Progyny's directors.
See More
Progyny Inc Stock Shows Oversold Signal
- Oversold Indicator: Progyny Inc (Ticker: PGNY) hit an RSI of 29.9 during Monday's trading, indicating an oversold condition as shares dipped to $17.77, suggesting that recent heavy selling may be nearing exhaustion, prompting investors to consider buying opportunities.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 36.7, PGNY's 29.9 RSI reflects relative weakness, potentially attracting investors looking for rebounds and increasing market participation.
- Historical Performance: PGNY's 52-week low stands at $16.755 and the high at $28.75, with the current trading price at $17.75, indicating potential rebound space within its volatility range, which may attract short-term traders.
- Investor Sentiment: As PGNY approaches its 52-week low, investor sentiment may shift to optimism, especially in light of the oversold signal, potentially encouraging more investors to seek entry points to capture potential rebounds.
See More
Progyny Leadership to Participate in Investor Conferences
- Investor Conference Schedule: Progyny's leadership team will participate in several investor conferences in March, including Leerink Partners, Barclays, and KeyBanc, showcasing the company's leadership in women's health and family building solutions.
- Executive Participation: CFO Mark Livingston will engage in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, while CEO Pete Anevski will participate in a fireside chat at the Barclays Global Healthcare Conference on March 11, enhancing the company's visibility.
- Technology Discussion: COO Melissa Cummings will join a panel discussion on fertility technology and women's health at the KeyBanc Capital Markets Healthcare Forum on March 17, highlighting Progyny's expertise and innovation in the field.
- Live Streaming: Live audiocasts and replays of all fireside chats will be available in the Events and Presentations section of Progyny's investor relations website, ensuring investors can stay updated on the company's latest developments.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Progyny Reports Record Revenue and EBITDA for 2025
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
See More
